Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Listerine, MD?

This article was originally published in The Tan Sheet

Executive Summary

Pfizer calls attention to the total health benefits associated with healthy oral care in its newest Listerine ad campaign launched Aug. 9. The new print ad shows a Listerine bottle wearing a stethoscope accompanied by the text, "If you think it's just for your mouth, think bigger." Results from a May survey conducted by the firm show 98% of dentists and 91% of physicians "indicate that they believe there is a link between oral health and overall health"; however, "whiter teeth" and a "better smile" are named most by consumers when asked to list the benefits of maintaining an oral hygiene regimen. The new ads counter competition from Procter & Gamble's year-old Crest Pro-Health rinse. Pfizer accepted a $16.6 bil. bid for its Consumer Healthcare division, including the Listerine brand, in June from Johnson & Johnson in an all-cash transaction expected to close by the end of 2006 (1"The Tan Sheet" July 3, 2006, p. 3)...

You may also be interested in...



J&J Picks Up Listerine, Nicorette With $16.6 Bil. Purchase Of Pfizer OTCs

Johnson & Johnson's successful bid to acquire Pfizer Consumer Healthcare extends the firm's reach in the global OTC market and provides entry into several new product categories

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel